Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 11 , ISSUE 3 ( May-June, 2019 ) > List of Articles

RESEARCH ARTICLE

Anti-Müllerian Hormone as a Surrogate Marker for Hormonal Dysfunction and Sonographic Pattern in Polycystic ovarian syndrome

Priyanka Sharma, Raina Chawla, Rashmi Ahuja, Usha Gupta

Keywords : Anti-Müllerian hormone, Hyperandrogenemia, Polycystic ovarian syndrome

Citation Information : Sharma P, Chawla R, Ahuja R, Gupta U. Anti-Müllerian Hormone as a Surrogate Marker for Hormonal Dysfunction and Sonographic Pattern in Polycystic ovarian syndrome. J South Asian Feder Obs Gynae 2019; 11 (3):175-180.

DOI: 10.5005/jp-journals-10006-1674

License: CC BY-NC 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2019; The Author(s).


Abstract

Aim: To examine the association of serum anti-Müllerian hormone (AMH) levels with biochemical derangement and sonographic appearance in PCOS women and to examine its role as a possible marker for diagnosis and prognosis of polycystic ovarian syndrome (PCOS). Materials and methods: This case-control study was conducted on patients attending the Gynecology OPD at ESIC Medical College and Hospital, Faridabad, Haryana from March 2017 to September 2017. 45 PCOS women and controls between 18 years and 45 years were recruited. Relevant clinical, biochemical, and sonographic data were collected. Linear regression was used to study the association between biochemical and sonographic variables and PCOS. Receiver-operating characteristic (ROC) curve analysis was performed for AMH, LH/FSH ratio, antral follicle count (AFC), and mean ovarian volume. The AMH cut-off value was determined for the prediction of PCOS. Results: Mean AMH levels were significantly higher in the PCOS group (5.9 v/s 2.36 ng/mL). In PCOS women, AMH levels positively correlated with AFC, mean ovarian volume, as well as androstenedione and testosterone levels. In controls, a significant positive correlation was found with serum testosterone and mean ovarian volume. An AMH had greater diagnostic potential for detecting PCOS compared to AFC, mean ovarian volume, and LH/FSH ratio. A threshold AMH value of 3.98 ng/mL had a sensitivity of 82.2% and a specificity of 93.3% for diagnosing PCOS. Conclusion: Serum AMH levels correlate well with hyperandrogenemia and sonographic features of PCOS and could be used as a marker for hormonal dysfunction and disease severity. Clinical significance: An AMH is a promising marker that could improve the diagnosis of PCOS and also help in establishing disease severity.

HTML PDF Share
  1. March WA, Moore VM, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–551. DOI: 10.1093/humrep/dep399.
  2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861. DOI: 10.1056/NEJM199509283331307.
  3. Dumesic DA, Oberfield SE, et al. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev 2015;36(5):487–525. DOI: 10.1210/er.2015-1018.
  4. Dewailly D, Lujan ME, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014 May–Jun;20(3):334–352. DOI: 10.1093/humupd/dmt061.
  5. Pepinsky RB, Sincalir LK, et al. Proteolytic processing of Müllerian inhibiting substance produces a transforming growth factor beta like fragment. J Biol Chem 1988;263:18961–18964.
  6. Weenen C, Laven JS, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83. DOI: 10.1093/molehr/gah015.
  7. Laven JS, Mulders AG, et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004 Jan;89(1):318–323. DOI: 10.1210/jc.2003-030932.
  8. Cassar S, Teede HJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol 2014;81:899–906. DOI: 10.1111/cen.12557.
  9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19–25. DOI: 10.1016/j.fertnstert.2003.10.004.
  10. Bhide P, Dilgil M, et al. Each small antral follicle in ovaries of women with polycystic ovary syndrome produces more antimüllerian hormone than its counterpart in a normal ovary: an observational cross-sectional study. Fertil Steril 2015 Feb;103(2):537–541. DOI: 10.1016/j.fertnstert.2014.10.033.
  11. Pellatt L, Hanna L, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007 Jan;92(1):240–245. DOI: 10.1210/jc.2006-1582.
  12. Saxena U, Ramani M, et al. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. J Obstet Gynaecol India 2018 Apr;68(2):117–122. DOI: 10.1007/s13224-017-1066-4.
  13. Sahmay S, Aydin Y, et al. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet 2014 Feb;31(2):213–220. DOI: 10.1007/s10815-013-0149-0.
  14. Zadehmodarres S, Heidar Z, et al. Anti-Müllerian hormon level and polycystic ovarian syndrome diagnosis. Iran J Reprod Med 2015;13(4):227–230.
  15. Wiweko B, Maidarti M, et al. Anti-Müllerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod and Genet 2014;31(10):1311–1316. DOI: 10.1007/s10815-014-0300-6.
  16. Köninger A, Koch L, et al. Anti-Müllerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet 2014;290(5):1023–1030. DOI: 10.1007/s00404-014-3317-2.
  17. Hayes E, Kushnir V, et al. Intra-cellular mechanism of Anti-Müllerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol 2016;433:56–65. DOI: 10.1016/j.mce.2016.05.019.
  18. Seifer DB, Merhi Z. Is AMH a regulator of follicular atresia? J Assist Reprod Genet 2014;31(11):1403–1407. DOI: 10.1007/s10815-014-0328-7.
  19. Piltonen T, Morin-Papunen L, et al. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20(7):1820–1826. DOI: 10.1093/humrep/deh850.
  20. Eldar-Geva T, Margalioth EJ, et al. Serum anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20(7):1814–1819. DOI: 10.1093/humrep/deh873.
  21. Tuten A, Sahmay S, et al. Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. Eur J Obstet Gynecol Reprod Biol 2014;177:121–125. DOI: 10.1016/j.ejogrb.2014.03.016.
  22. Rosenfield RL, Wroblewski K, et al. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril 2012 Jul;98(1):242–249. DOI: 10.1016/j.fertnstert.2012.03.059.
  23. Eilertsen TB, Vanky E, et al. Anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012 Aug;27(8):2494–2502. DOI: 10.1093/humrep/des213.
  24. Pigny P, Merlen E, et al. Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003 Dec;88(12):5957–5962. DOI: 10.1210/jc.2003- 030727.
  25. Dewailly D. Diagnostic criteria for PCOS: Is there a need for a rethink? Best Pract Res Clin Obstet Gynaecol 2016 Nov;37:5–11. DOI: 10.1016/j.bpobgyn.2016.03.009.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.